je.st
news
Tag: orphan
a Norwood biotech gets first of three potential orphan drug designations
2015-06-13 17:54:32| Biotech - Topix.net
A 10-employee Norwood biotech has received the first of what it expects will be three orphan drug designations from the Food and Drug Administration for a drug it bought last year from a professor at UMass Medical Center in Worcester. Corbus Pharmaceuticals , which just started trading on the Nasdaq exchange in April, has been known among investors mostly for its plan to develop the drug to treat inflammation associated with cystic fibrosis which could potentially be used in conjunction with the suite of drugs being produced at Boston-based Vertex Pharmaceuticals .
Tags: potential
drug
biotech
designations
Swedish Orphan Plunges After Talks End on Potential Takeover
2015-06-09 02:52:46| Appliances - Topix.net
Swedish Orphan Biovitrum AB fell as much as 19 percent after the maker of treatments for rare diseases said it ended talks on a possible takeover offer. The drugmaker, better known as Sobi, has held talks with potential buyers since last year, Bloomberg reported in April, citing people familiar with the matter.
Tags: end
potential
talks
swedish
Morning Links: Orphan works. Fighting the bad guys. WiFi-powered camera and Big Brother.
2015-06-05 19:02:30| Wireless - Topix.net
The Report documents the legal and business challenges faced by good faith users who seek to use orphan works and/or engage in mass digitization projects. The TeleRead Take: Slow progress on this issue, but still, progress.
Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
2015-06-03 06:41:56| drugdiscoveryonline Home Page
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced recently that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to revusiran, an investigational RNAi therapeutic, for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis)
Tags: united
states
united states
food
FDA Grants Orphan Drug Designation For DCR-PH1, Dicerna's Investigational Therapy For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
2015-04-29 05:21:48| drugdiscoveryonline Home Page
Dicerna Pharmaceuticals, Inc., a leading developer of RNA interference (RNAi) therapeutics, recently announced that the U.S
Tags: type
primary
treatment
drug